Pioglitazone reduces central obesity in polycystic ovary syndrome women

References

• Frank S. Polycystic ovary syndrome. N Engl J Med 1995;333:853–861.
   PubMed Web of Science ®Google Scholar
• Svendsen PF, Nilas L, Nørgaard K, Jensen JE, Madsbad S. Obesity, body composition and metabolic disturbances in polycystic ovary syndrome. Hum Reprod 2008;23:2113–2121.
   PubMed Web of Science ®Google Scholar
• Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078–3082.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41:1257–1266.
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800.
   PubMed Web of Science ®Google Scholar
• Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 2005;90:60–65.
   PubMed Web of Science ®Google Scholar
• Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2562–2568.
   PubMed Web of Science ®Google Scholar
• Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, Lanzone A. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003;18:1210–1218.
   PubMed Web of Science ®Google Scholar
• Heikkinen S, Auwerx J, Argmann CA. PPARgamma in human and mouse physiology. Biochim Biophys Acta 2007;1771:999–1013.
   PubMed Web of Science ®Google Scholar
• Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:3835–3840.
   PubMed Web of Science ®Google Scholar
• Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanovà L, Nardo LG, et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:2–5.
   PubMed Web of Science ®Google Scholar
• Nasiek M, Kos-Kudla B, Ostrowska Z, Marek B, Kudla M, Sieminska L, Kajdaniuk D, et al. Acute phase proteins: C-reactive protein and fibrinogen in young women with polycystic ovary syndrome. Pathophysiology 2007;14:23–28.
   PubMedGoogle Scholar
• Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929–1935.
   PubMed Web of Science ®Google Scholar
• Pasquali R, Gambineri A. Targeting insulin sensitivity in the treatment of polycystic ovary syndrome. Expert Opin Ther Targets 2009;13:1205–1226.
   PubMed Web of Science ®Google Scholar
• Koenen TB, Tack CJ, Kroese JM, Hermus AR, Sweep FC, van der Laak J, Stalenhoef AF, et al. Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients. J Clin Endocrinol Metab 2009;94:4453–4457.
   PubMed Web of Science ®Google Scholar
• Fissoune R, Pellet N, Chaabane L, Contard F, Guerrier D, Briguet A. Evaluation of adipose tissue distribution in obese fa/fa Zucker rats by in vivo MR imaging: effects of peroxisome proliferator-activated receptor agonists. MAGMA 2004;17:229–235.
   PubMedGoogle Scholar
• Kolak M, Yki-Järvinen H, Kannisto K, Tiikkainen M, Hamsten A, Eriksson P, Fisher RM. Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab 2007;92:720–724.
   PubMed Web of Science ®Google Scholar
• Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 2004;27:1660–1667.
   PubMed Web of Science ®Google Scholar
• Carmina E. Cardiovascular risk and events in polycystic ovary syndrome. Climacteric 2009;12 Suppl 1:22–25.
   PubMed Web of Science ®Google Scholar
• Rachon D, Teede H. Ovarian function and obesity–interrelationship, impact on women’s reproductive lifespan and treatment options. Mol Cell Endocrinol 2010;316:172–179.
   PubMed Web of Science ®Google Scholar
• de Zegher F, Lopez-Bermejo A, Ibáñez L. Adipose tissue expandability and the early origins of PCOS. Trends Endocrinol Metab 2009;20:418–423.
   PubMed Web of Science ®Google Scholar
• Hirschberg AL. Polycystic ovary syndrome, obesity and reproductive implications. Womens Health (Lond Engl) 2009;5:529–40; quiz 541.
   PubMedGoogle Scholar
• Capolu I, Erdem F, Uyanik A, Turhan H. Serum levels of resistin and hsCRP in women with PCOS. European Journal of Medicine 2009;4:428–433.
   Google Scholar
• Ortega-González C, Luna S, Hernández L, Crespo G, Aguayo P, Arteaga-Troncoso G, Parra A. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1360–1365.
   PubMed Web of Science ®Google Scholar